A 54-year-old male presented with complex partial seizures, mild eosinophilia (10%) and a normal WBC count in April 2000. Over the next 2 years his clinical history was notable for the development of Klebsiella pneumonia Â 2, 16 episodes of acute bronchitis and persistent eosinophilia.
In January 2003, a bone marrow biopsy showed increased eosinophils (10%), magnetic resonance imaging (MRI) of the brain was normal, and multiple stool samples were negative for ova and parasites, including Strongyloides stercoralis. A diagnosis of idiopathic hypereosinophilic syndrome (IHES) was made, based on classic criteria 1 defined as: absolute eosinophil count 41500 for 46 months, no underlying cause for eosinophilia, and signs and symptoms of organ involvement (seizures, bronchitis and pneumonia). No therapy was offered at that point. The diagnosis was confirmed at UT-MDACC in October 2003. The patient had always resided in the Gulf coast area at the Texas-Louisiana border. There was no significant travel history within or outside the US.
Owing to persistent eosinophilia and systemic respiratory and neurologic symptoms, the patient was treated with several lines of treatment for IHES. These treatments included imatinib 400 mg daily (October- In July 2005, the patient underwent a matched unrelated donor bone marrow transplant from a 10/10 allele matched donor. The preparative regimen consisted of fludarabine, melphalan and thymoglobulin. Methotrexate and tacrolimus were used for graft-versus-host disease (GVHD) prophylaxis.
His post transplant course was marked by persistent nausea, vomiting, epigastric pain and bloating that started within 3 weeks of transplant. An esophagogastroduodenoscopy (EGD) was unremarkable. Colonoscopy and rectal biopsy showed acute GVHD that was treated with methylprednisolone 2 mg/kg but his symptoms persisted. A second EGD was performed due to persistent symptoms. The duodenal biopsy from the second procedure showed helminthic larva, identified as Strongyloides stercoralis ( Figure 1 ). With this new finding, patient was started on treatment for strongyloidiasis with ivermectin (200 mcg/kg) 18 mg orally for 3 days and thiabendazole 500 mg twice-aday orally for 10 days.
The patient developed acute respiratory failure requiring endotracheal intubation and mechanical ventilation. Bronchoalveolar lavage cultures only grew Candida glabrata. Aggressive antifungal therapy and stress dose corticosteroids, along with subcutaneous ivermectin and oral thiabendazole were continued. He developed multiorgan failure requiring vasopressors and hemodialysis, and died 1 week later of respiratory failure. Limited autopsy was performed, and showed diffuse alveolar damage with interstitial fibrosis, intra-alveolar hemorrhage and bilateral pleural effusion. No organisms, including Strongyloides stercoralis, were detected by histology or culture.
Hypereosinophilic syndromes are a heterogeneous group of uncommon disorders characterized by marked eosinophilia in the peripheral blood and/or tissues often without an identifiable cause. The traditional diagnosis of HES was based on classical critera.
1 Patients generally present with hepatosplenomegaly, anemia, thrombocytopenia, and bone marrow dysplasia or fibrosis, and their clinical course is similar to that of a myeloproliferative disease. The therapeutic objective for patients with HES has been to limit organ damage by controlling the eosinophil count.
Common treatments include prednisone, hydroxyurea and interferon-a, 2 the tyrosine kinase inhibitor, imatinib mesylate, 3 and the nucleoside analog, cladribine. 4 Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity preparative regimens has recently been used in HES. Strongyloides stercoralis, an intestinal nematode, infects more than 100 million individuals worldwide, including 400 000 in Puerto Rico and the southeastern US. It is generally acquired by penetration of the skin by soildwelling filariform larvae, or ingestion of filariformcontaminated food. It can produce marked autoinfection or hyperinfection in debilitated and immunosuppressed patients. 6 Fifty percent of the infected individuals are asymptomatic and about 75% manifest eosinophilia. Common symptoms are epigastric pain and tenderness. In some patients pulmonary eosinophilia can mimic bronchial asthma. 7 Massive hyperinfection in immunosuppressed patients can produce severe enterocolitis and widespread dissemination to heart, lungs and central nervous system.
The diagnosis is usually made by finding the rhabditiform larvae in the stool, although there is a high rate of false negatives even when serial samples are tested. When absent from the stool, larvae may sometimes be found in duodenal aspirates or jejunal biopsy specimens. 8 All infected patients should be treated to prevent the serious consequences of hyperinfection. The drugs of choice are ivermectin and thiabendazole for 2-3 days.
9,10 Albendazole, though still not approved by FDA, is an alternative. Therapy must be extended for 7 to 10 days in hyperinfection syndromes, with a repeat course 2 weeks later. 9, 10 The patient described in this report came from an endemic area for strongyloides infection. He presumably had subclinical infection manifesting as eosinophilia and recurrent pulmonary symptoms. Persistent eosinophilia, symptomatic pulmonary and neurologic involvement, and absence of any identifiable cause despite extensive testing led to a diagnosis of IHES. After failing multiple conventional therapies, the patient underwent a nonmyeloablative matched-unrelated donor stem cell transplant. His post transplant course was complicated by acute GVHD, opportunistic infections and subsequently, pneumonitis with diffuse alveolar hemorrhage which proved fatal.
In view of this case we have modified our practice algorithm for patients referred for allogeneic transplantation for HES. Owing to the low sensitivity of the available diagnostic testing for strongyloidiasis, 8 patients coming from or with a history of travel to endemic areas will be given an empirical course of antihelminthic therapy to treat any subclinical parasitic infection. Cytotoxic therapy or allogeneic HSCT will be used only if eosinophilia persists after a course of antihelminthics.
In conclusion, occult strongyloides infection may produce chronic eosinophilia, mimicking idiopathic hypereosinophilic syndrome. This diagnosis should be excluded by rigorous evaluation before initiation of cytotoxic treatment for IHES. Moreover, for patients coming from endemic areas, we believe an empirical course of antiparasitic therapy should be given to treat the possible subclinical parasitic infection.
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